RIC1 Antibody | CSB-PA671121LA01HU

(No reviews yet) Write a Review
SKU:
CSB-PA671121LA01HU
Availability:
3 to 7 Working Days
  • RIC1 Antibody
  • Immunohistochemistry of paraffin-embedded human pancreatic cancer using CSB-PA671121LA01HU at dilution of 1:100
  • Immunofluorescent analysis of HepG2 cells using CSB-PA671121LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L)
$378.96 - $586.44

Description

RIC1 Antibody | CSB-PA671121LA01HU | Cusabio

RIC1 Antibody is Available at Gentaur Genprice with the fastest delivery.

Online Order Payment is possible or send quotation to info@gentaur.com.

Product Type: Polyclonal Antibody

Target Names: RIC1

Aliases: RAB6A-GEF complex partner protein 1 (Connexin-43-interacting protein of 150 kDa) (Protein RIC1 homolog), RIC1, CIP150 KIAA1432

Background: The RIC1-RGP1 complex acts as a guanine nucleotide exchange factor (GEF), which activates RAB6A by exchanging bound GDP for free GTP and may thereby required for efficient fusion of endosome-derived vesicles with the Golgi compartment. The RIC1-RGP1 complex participates in the recycling of mannose-6-phosphate receptors. Required for phosphorylation and localization of GJA1.

Isotype: IgG

Conjugate: Non-conjugated

Clonality: Polyclonal

Uniport ID: Q4ADV7

Host Species: Rabbit

Species Reactivity: Human

Immunogen: Recombinant Human RAB6A-GEF complex partner protein 1 protein (951-1233AA)

Immunogen Species: Human

Applications: ELISA, IHC, IF

Tested Applications: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200

Purification Method: >95%, Protein G purified

Dilution Ratio1: ELISA:1:2000-1:10000

Dilution Ratio2: IHC:1:20-1:200

Dilution Ratio3: IF:1:50-1:200

Dilution Ratio4:

Dilution Ratio5:

Dilution Ratio6:

Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form: Liquid

Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Initial Research Areas: Others

Research Areas: Others

View AllClose

0 Reviews

View AllClose